Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Lipella Pharmaceuticals Inc. stock logo
LIPO
Lipella Pharmaceuticals
$0.78
-4.9%
$2.30
$0.62
$12.00
$3.48M-0.08729,737 shs2,156 shs
NKGen Biotech, Inc. stock logo
NKGN
NKGen Biotech
$0.30
$0.27
$0.10
$1.37
$13.48M1.261.58 million shs46,117 shs
Panbela Therapeutics, Inc. stock logo
PBLA
Panbela Therapeutics
$0.16
+1.9%
$0.25
$0.15
$0.47
$777K1.3418,446 shs32,278 shs
Palatin Technologies Inc stock logo
PTN
Palatin Technologies
$0.09
-44.6%
$0.11
$0.09
$2.48
$2.45M0.942.28 million shs14.57 million shs
Reduce the Risk Cover

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Lipella Pharmaceuticals Inc. stock logo
LIPO
Lipella Pharmaceuticals
0.00%-13.33%-73.91%-66.38%-78.80%
NKGen Biotech, Inc. stock logo
NKGN
NKGen Biotech
0.00%+24.90%-11.76%+130.77%-77.61%
Panbela Therapeutics, Inc. stock logo
PBLA
Panbela Therapeutics
0.00%-23.81%-43.68%-46.67%-56.40%
Palatin Technologies Inc stock logo
PTN
Palatin Technologies
0.00%0.00%0.00%+9,409,900.00%+9,409,900.00%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Lipella Pharmaceuticals Inc. stock logo
LIPO
Lipella Pharmaceuticals
1.3131 of 5 stars
0.05.00.00.00.03.30.6
NKGen Biotech, Inc. stock logo
NKGN
NKGen Biotech
N/AN/AN/AN/AN/AN/AN/AN/A
Panbela Therapeutics, Inc. stock logo
PBLA
Panbela Therapeutics
0.0817 of 5 stars
0.03.00.00.00.60.00.0
Palatin Technologies Inc stock logo
PTN
Palatin Technologies
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Lipella Pharmaceuticals Inc. stock logo
LIPO
Lipella Pharmaceuticals
0.00
N/AN/AN/A
NKGen Biotech, Inc. stock logo
NKGN
NKGen Biotech
0.00
N/AN/AN/A
Panbela Therapeutics, Inc. stock logo
PBLA
Panbela Therapeutics
2.00
HoldN/AN/A
Palatin Technologies Inc stock logo
PTN
Palatin Technologies
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Lipella Pharmaceuticals Inc. stock logo
LIPO
Lipella Pharmaceuticals
$536.36K6.50N/AN/A$1.59 per share0.49
NKGen Biotech, Inc. stock logo
NKGN
NKGen Biotech
N/AN/AN/AN/A($2.68) per shareN/A
Panbela Therapeutics, Inc. stock logo
PBLA
Panbela Therapeutics
N/AN/AN/AN/A($18.37) per shareN/A
Palatin Technologies Inc stock logo
PTN
Palatin Technologies
$350K6.99N/AN/AN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Lipella Pharmaceuticals Inc. stock logo
LIPO
Lipella Pharmaceuticals
-$5.02M-$4.08N/AN/A-988.83%-224.08%-172.88%N/A
NKGen Biotech, Inc. stock logo
NKGN
NKGen Biotech
-$82.94M-$2.45N/AN/AN/AN/A-479.36%N/A
Panbela Therapeutics, Inc. stock logo
PBLA
Panbela Therapeutics
-$25.26M-$71.13N/AN/AN/AN/A-302.61%7/7/2025 (Estimated)
Palatin Technologies Inc stock logo
PTN
Palatin Technologies
N/A-$1.55N/AN/AN/AN/AN/AN/A

Latest PBLA, NKGN, PTN, and LIPO Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/14/2025Q1 2025
Lipella Pharmaceuticals Inc. stock logo
LIPO
Lipella Pharmaceuticals
N/A-$0.64N/A-$0.64N/A$0.13 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Lipella Pharmaceuticals Inc. stock logo
LIPO
Lipella Pharmaceuticals
N/AN/AN/AN/AN/A
NKGen Biotech, Inc. stock logo
NKGN
NKGen Biotech
N/AN/AN/AN/AN/A
Panbela Therapeutics, Inc. stock logo
PBLA
Panbela Therapeutics
N/AN/AN/AN/AN/A
Palatin Technologies Inc stock logo
PTN
Palatin Technologies
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Lipella Pharmaceuticals Inc. stock logo
LIPO
Lipella Pharmaceuticals
N/A
6.21
6.21
NKGen Biotech, Inc. stock logo
NKGN
NKGen Biotech
N/A
0.02
0.02
Panbela Therapeutics, Inc. stock logo
PBLA
Panbela Therapeutics
N/A
0.26
0.26
Palatin Technologies Inc stock logo
PTN
Palatin Technologies
N/AN/AN/A

Institutional Ownership

CompanyInstitutional Ownership
Lipella Pharmaceuticals Inc. stock logo
LIPO
Lipella Pharmaceuticals
74.31%
NKGen Biotech, Inc. stock logo
NKGN
NKGen Biotech
76.17%
Panbela Therapeutics, Inc. stock logo
PBLA
Panbela Therapeutics
4.37%
Palatin Technologies Inc stock logo
PTN
Palatin Technologies
11.50%

Insider Ownership

CompanyInsider Ownership
Lipella Pharmaceuticals Inc. stock logo
LIPO
Lipella Pharmaceuticals
32.11%
NKGen Biotech, Inc. stock logo
NKGN
NKGen Biotech
10.36%
Panbela Therapeutics, Inc. stock logo
PBLA
Panbela Therapeutics
0.01%
Palatin Technologies Inc stock logo
PTN
Palatin Technologies
7.10%
CompanyEmployeesShares OutstandingFree FloatOptionable
Lipella Pharmaceuticals Inc. stock logo
LIPO
Lipella Pharmaceuticals
44.47 million3.03 millionNot Optionable
NKGen Biotech, Inc. stock logo
NKGN
NKGen Biotech
N/A44.95 million40.29 millionNot Optionable
Panbela Therapeutics, Inc. stock logo
PBLA
Panbela Therapeutics
64.86 million4.86 millionNot Optionable
Palatin Technologies Inc stock logo
PTN
Palatin Technologies
3026.01 millionN/AN/A

Recent News About These Companies

PL9643 shows promise in dry eye disease treatment

New MarketBeat Followers Over Time

Media Sentiment Over Time

Lipella Pharmaceuticals stock logo

Lipella Pharmaceuticals NASDAQ:LIPO

$0.78 -0.04 (-4.85%)
As of 07/3/2025 12:40 PM Eastern

Lipella Pharmaceuticals Inc., a biotechnology company, focuses on developing drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for various applications. The company develops LP-10, a formulation of tacrolimus that has completed Phase 2a clinical trial for patients with radiation-induced hemorrhagic cystitis; LP-310, a formulation of tacrolimus for the treatment of oral lichen planus; and LP-410, an oral liposomal formulation of tacrolimus for the treatment of oral graft-versus-host disease (GVHD). Lipella Pharmaceuticals Inc. was incorporated in 2005 and is headquartered in Pittsburgh, Pennsylvania.

NKGen Biotech stock logo

NKGen Biotech NYSE:NKGN

$0.30 0.00 (0.00%)
As of 07/3/2025 12:47 PM Eastern

NKGen Biotech, Inc. operates as a clinical-stage biotechnology company that focuses on the development and commercialization of autologous, allogeneic, and CAR-NK natural killer cell therapies. It develops SNK01, an autologous NK cell therapy; and SNK02, an allogeneic NK cell therapy, which are in Phase 1 clinical trials. The company was founded in 2017 and is based in Santa Ana, California.

Panbela Therapeutics stock logo

Panbela Therapeutics NASDAQ:PBLA

$0.16 +0.00 (+1.91%)
As of 07/3/2025 12:09 PM Eastern

Panbela Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of disruptive therapeutics for the treatment of patients with urgent unmet medical needs. The company's lead product candidates are Ivospemin (SBP-101), a proprietary polyamine analogue, which has completed Phase Ia/Ib clinical trial for the treatment of patients with metastatic pancreatic ductal adenocarcinoma; Flynpovi, a combination of eflornithine (CPP-1X) and sulindac which is in Phase III clinical trials; and Eflornithine, an enzyme-activated irreversible inhibitor of the enzyme ornithine decarboxylase, currently under Phase I/II trial. It has a research agreement with the Johns Hopkins University School of Medicine for the development of ivospemin. The company was formerly known as Sun BioPharma, Inc. and changed its name to Panbela Therapeutics, Inc. in December 2020. Panbela Therapeutics, Inc. was incorporated in 2011 and is based in Waconia, Minnesota.

Palatin Technologies stock logo

Palatin Technologies NYSE:PTN

$0.09 -0.08 (-44.65%)
As of 05/7/2025

Palatin Technologies, Inc., a biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the United States. The company's lead product is Vyleesi, a melanocortin receptor (MCr) agonist for the treatment of premenopausal women with hypoactive sexual desire disorder. It is also developing oral PL8177, a selective MC1r agonist peptide that has completed Phase I clinical trial for the treatment of inflammatory bowel diseases. In addition, the company engages in the development of PL9643, a peptide melanocortin agonist active at multiple MCrs, including MC1r and MC5r for anti-inflammatory ocular indications, such as dry eye disease; and melanocortin peptides for diabetic retinopathy. Further, it is developing PL3994, a natriuretic peptide receptor (NPR)-A agonist and synthetic mimetic of the endogenous neuropeptide hormone atrial natriuretic peptide for cardiovascular indications; and PL5028, an NPR-A and NPR-binder to treat cardiovascular and fibrotic diseases, including reducing cardiac hypertrophy and fibrosis. The company was incorporated in 1986 and is based in Cranbury, New Jersey.